The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of ...

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...

Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to ...

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment ...

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...

The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a ...

The startup is built around technology it claims can help get after known, but undruggable cancer targets and design ...

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...

The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...